Skip to main content
. 2022 Nov 12;13:6903. doi: 10.1038/s41467-022-34703-w

Fig. 4. Association between the PSGC and survival benefits from adjuvant chemotherapy in stage II and stage III GC.

Fig. 4

a Survival benefits from adjuvant chemotherapy for the low-PSGC patients in the training cohort. b Survival benefits from adjuvant chemotherapy for the high-PSGC patients in the training cohort. c Survival benefits from adjuvant chemotherapy for the low-PSGC patients in the validation cohort. d Survival benefits from adjuvant chemotherapy for the high-PSGC patients in the validation cohort. e Survival benefits from adjuvant chemotherapy for the low-PSGC patients in the total cohort. f Survival benefits from adjuvant chemotherapy for the high-PSGC patients in the total cohort. The comparisons of OS and DFS between the two groups are performed using a two-sided log-rank test. PSGC pathomics signature of gastric cancer, GC gastric cancer, Chemo chemotherapy. Source data are provided as a Source data file.